← Eichor
Study identifier: NCT06130046 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

Condition: Kidney Transplant; Complications · Liver Transplant; Complications  ·  Sponsor: University of Rome Tor Vergata

PhaseN/A
Planned participants300
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.

This description comes directly from the study's public registry record.

Talk to the study team

Roberta Angelico, PhD FEBS  ·  0620908294  ·  roberta.angelico@med.uniroma2.it

Domiziana Pedini, MD  ·  +393488869569  ·  domiziana.pedini@libero.it

Always discuss trial participation with your own doctor first.

Locations (1)

University of Rome Tor VergataRome, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06130046